Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 941-183-5 | CAS number: -
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
- Absorption rate - oral (%):
- 100
Additional information
No specific study was performed on the absorption, distribution, metabolism, excretion (ADME) of this substance (EP-49-10P2), but data are currently available fromin vivotoxicology studies.
The substance, EP-49-10P2, is a UVCB substance composed of 10%-20% phosphoric acid esters of BADGE (bisphenol A diglycidyl ethers, CAS 1675-54-3) which are dissolved in BADGE (80%-90%). The substance is a very viscous liquid and has low water solubility. An experimental value of 82 mg/l was determined after six days. However, the epoxide groups of BADGE are known to hydrolyse to the respective diol-groups increasing water solubility over time.
Themolecular weight (MW) of BADGE monomer amounts to 340 Da; dimers and trimers have higher MW. The molecular weights of the esters range from approx. 1200 Da to 3500 Da. Determination of the surface activity of EP-49-10P2 indicated that the substance has surface activity. Accordingly, there is no true value for lipophilicity.
The vapour pressure of BADGE is very low (approx. 5 x 10^-8 Pa).
Based on the fact that the substance EP-49-10P2 contains 80%-90% BADGE it is concluded that the toxic properties of the substance EP-49-10P2 are the same as those of BADGE. Accordingly, read-across was made in the present REACH registration dossier from study results obtained with BADGE.
After oral exposure to EP-49-10P2 absorption ofBADGEand systemic distribution is to be expected based on the low molecular weight. In repeat dose feeding studies performed with BADGE effects in several organs were observed at high doses indicating systemic distribution.
Systemic availability of EP-49-10P2 after dermal application is expected to be low based on the very viscous form of the substance. However, due to skin irritating and sensitising properties of BADGE skin permeability might be increased after dermal contact.
Availability of EP-49-10P2 under a vapour state can be excluded because of its very low vapour pressure; formation of inhalable aerosols from the very viscous liquid is unlikely.
There is no information on metabolism and excretion of EP-49-10P2.
Based on the available information the bioaccumulation potential of EP-49-10P2 cannot be assessed.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
